The FDA has issued a complete response letter (CRL) for Johnson and Johnson’s proposed rheumatoid arthritis (RA) drug, sirukumab. Janssen Biotech, a division of Johnson and Johnson, had filed a Biologics License Application (BLA) for the interleukin-6 (IL-6) inhibitor, including data from a global phase 3 clinical development program, in September 2016.
The FDA has issued a complete response letter (CRL) for Johnson and Johnson’s proposed rheumatoid arthritis (RA) drug, sirukumab. Janssen Biotech, a division of Johnson and Johnson, had filed a Biologics License Application (BLA) for the interleukin-6 (IL-6) inhibitor, including data from a global phase 3 clinical development program, in September 2016.
“We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab in the treatment of moderately to severely active rheumatoid arthritis,” said Newman Yeilding, MD, head of immunology development for Janssen. “We believe sirukumab represents an important therapeutic option for patients living with rheumatoid arthritis, especially for those individuals who cycle through multiple treatments and continue to struggle to find an effective option for a potentially disabling disease.”
The CRL for sirukumab does not come as a surprise to the rheumatology world; the FDA’s rejection of the drug follows an August 2, 2017, Arthritis Advisory Committee (AAC) meeting in which the voting committee members did not recommend drug approval. The AAC expressed concerns about 35 patient deaths reported during a phase 3 clinical program in patients with RA, 34 of which occurred in the sirukumab arm of the study. The most common causes of death included major cardiac adverse events (AEs), infection, and malignancy.
Sirukumab was also associated with laboratory abnormalities (decreased neutrophil count; increased liver function test values; and increased lipid parameters, including low-density lipoprotein, high-density lipoprotein, and triglycerides). These abnormalities were documented with both the 50-mg and 100-mg doses of sirukumab that were studied.
Janssen has been among several companies seeking to retain a hold on the increasingly crowded RA marketplace in the face of increasing biosimilar competition for an established biologic as its innovator infliximab (Remicade). By developing an IL-6 inhibitor for use in patients who had not had an adequate response to such products as Remicade, Janssen had likely hoped to buffer itself against further erosions of its sales from infliximab biosimilars Inflectra and Renflexis. With sirukumab’s rejection by the FDA, Janssen lags behind such approved IL-6 drugs as sarilumab (manufactured by Sanofi) and tocilizumab (Acterma) manufactured by Roche).
Janssen said that it would review the details of the CRL and create a plan for follow-up discussions of the drug’s rejection with the FDA. The company hopes to, as Yeilding said, “Gain a full understanding of FDA requirements for US approval.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.